A Multiple Center, Open Label, Prospective Study to Evaluate the Effectiveness and Ease-Of-Use of AMG504-1 Administered in the Home or School Environments for Treating Hypoglycemia in Children and Adolescents With T1D
Phase of Trial: Phase III
Latest Information Update: 02 Jun 2017
At a glance
- Drugs Glucagon (Primary)
- Indications Hypoglycaemia
- Focus Registrational; Therapeutic Use
- Sponsors Eli Lilly; Locemia Solutions
- 02 Jun 2017 Status changed from active, no longer recruiting to completed.
- 07 Mar 2016 Planned End Date changed from 1 Dec 2015 to 1 May 2016, according to ClinicalTrials.gov record.
- 10 Aug 2015 Planned primary completion date changed from 1 Jun 2015 to 1 Aug 2015 as per ClinicalTrials.gov record.